Piper Jaffray Starts Adamas Pharmaceuticals (ADMS) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
William Blair Starts Adamas Pharmaceuticals (ADMS) at Outperform
May 5, 2014 7:31 AM EDTWilliam Blair initiated coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with an Outperform rating and a price target of $35.00.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.
... MoreCredit Suisse Starts Adamas Pharmaceuticals (ADMS) at Outperform
May 5, 2014 7:31 AM EDTCredit Suisse initiated coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with an Outperform rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.
Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.
... MoreNeedham & Company Starts Adamas Pharmaceuticals (ADMS) at Buy
May 5, 2014 6:21 AM EDTNeedham & Company initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Buy rating and a price target of $33.00.
Analyst Elliot Wilbur comments, "We are initiating coverage of Adamas Pharmaceuticals, a specialty pharma play with a validated platform for developing and commercializing pharmacokinetically enhanced... More
